NCT01734850: A reported trial by Calimmune, Inc.
This trial has reported on time, in line with the regulations.
Full data
Full entry on ClinicalTrials.gov | NCT01734850 |
---|---|
Title | An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART |
Results Status | Reported |
ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
Start date | April 30, 2013 |
Completion date | Sept. 30, 2017 |
Required reporting date | Sept. 30, 2020, midnight |
Actual reporting date | June 25, 2020 |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |